πŸ‡ΊπŸ‡Έ

US SEC Filing Intelligence

Β· daily

Nasdaq 100 Stocks SEC Filings β€” March 16, 2026

Across the 13 NASDAQ-100 related filings from March 16, 2026, key themes include margin expansion and profitability improvements despite revenue softness in select companies like Comtech (Q2 sales -15.6% YoY but gross margin +720 bps to 33.9%, Adjusted EBITDA +214% to $9.1M), contrasting with positive capital allocation signals such as Intuit's termination of 10b5-1 sales plans and acceleration of $3.5B share repurchases (H1 repurchases +40% YoY to $1.8B). Amazon's €14.5B Euro notes issuance at low coupons (2.8%-4.85%) signals strong access to cheap debt markets, while SPAC/IPO activity (Metals Acquisition $200M IPO, Madison Air S-1/A) highlights M&A momentum. Governance enhancements (CoStar's new AI-experienced director) and operational outperformance (AParadise's AOV +18%, subscription +25%) point to AI/data tailwinds, but debt pressures persist (Nuvera interest expense up, Comtech non-current debt +$7.9M to $103.5M). Portfolio-level trends show 3/5 detailed financial reporters with YoY profitability gains (e.g., Comtech H1 gross profit +51.3%, Nuvera net income +107.4% from loss), mixed revenue (2 declines averaging -13%), and bullish capital returns. Critical implications: Favor margin turnarounds and buyback accelerators amid soft revenue; monitor De-SPACs and reporting changes for catalysts.

8 high priority 5 medium 13 total filings
Β· daily

Dow Jones 30 Stocks SEC Filings β€” March 16, 2026

Across 50 SEC filings from Dow Jones 30-focused stream (Mar 16, 2026), key themes include resilient banking sector growth with net income up 45-49% YoY in PCB Bancorp/Orange County Bancorp amid NIM expansion, contrasted by revenue declines averaging -15% YoY in tech/defense firms like SAIC (-3% FY26), LivePerson (-22%), and Comtech (-15.6% Q2 FY26), though margins improved (e.g., Comtech gross margin +720bps to 33.9%). M&A activity surged with 6 deals (Interactive Strength/Ergatta $3.5M+$5-9.5M stock, Allison/Dana $2.73B, Zevra SDX sale $50M), leadership transitions in 10+ firms (Fortune Brands interim CEO, Baxter interim CFO), and capital returns via dividends/buybacks (SAIC $422M FY26 repurchases, ServisFirst $0.38/share). Mixed sentiment dominates (18/50), with forward guidance cautious (SAIC FY27 rev -4-2% organic) but clinical catalysts (Perspective VMT-Ξ±-NET mid-2026 data) and bank efficiency gains (PCB ROA 1.15% +). Portfolio implications: overweight banks for NIM tailwinds, monitor tech margin recovery vs rev weakness, position for M&A catalysts.

27 high priority 23 medium 50 total filings
Β· daily

US SEC Filings Daily Market Digest β€” March 16, 2026

Across 50 SEC filings for March 16, 2026, mixed FY2025 financials dominate with 12/20 10-Ks showing revenue declines averaging -10% YoY (e.g., Townsquare -5.2%, iQIYI -6.6%, LivePerson -22%) offset by outliers like Figure Technology +48.7% and WaterBridge +66%, while margins improved in 7/15 cases via cost cuts (e.g., Townsquare op income +103.8%). M&A and restructuring activity surges in real estate (Kennedy-Wilson amendment, Armada Hoffler $562M sale) and biotech/pharma (Alto Neuroscience pipeline, Urgent.ly merger), alongside capital returns like Amphastar $50M buyback increase and Townsquare $0.20 dividend maintenance. Management transitions signal continuity (CoStar AI expert director, KORU CEO succession), but risks loom from widening losses (Alto -3% YoY net loss) and leverage rises (WaterBridge borrowings +140% YoY). Sector pivots to AI/HPC (Mawson, CoStar) and positive guidance (Townsquare FY2026 $420-440M revenue) point to recovery potential, with portfolio-level trends favoring cost discipline amid soft revenue. Implications: Favor resilient growth names like PCB Bancorp (+45% net income) and Blend Labs (loss narrowing to $7M), monitor merger votes for catalysts.

31 high priority 19 medium 50 total filings
Β· daily

S&P 500 Consumer Discretionary Sector SEC Filings β€” March 16, 2026

Across the 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (despite diverse inclusions like infra/energy/crypto), mixed sentiment dominates with 18/50 showing mixed signals, driven by robust revenue growth in select names (e.g., Forgent Power +69% YoY Q2 rev to $296M, Figure Tech +48.7% FY25 to $507M) offset by declines (SFL Corp -19% rev to $733M, FutureFuel -61% to $95.7M). Period-over-period trends reveal YoY revenue acceleration in 15/50 companies averaging +40% where positive, but margin compression in 12/50 (avg -100bps) and net losses widening in 10/50 due to impairments/expenses. Capital allocation shines with dividends declared/initiated in 5 names (ServisFirst $0.38/shr, WaterBridge $0.05/shr quarterly) and buybacks noted (Truist $10B program, Marathon $4.5B returned). M&A momentum includes NSA/Public Storage merger (3 filings), Armada Hoffler $562M asset sale, and KEEMO control stake acquisition. Forward-looking guidance is bullish in infra/power (Forgent FY26 rev $1.275-1.325B +73%), with April 2026 AGMs (Ferguson, Truist, Marathon) as key catalysts. Crypto ETF index changes (Grayscale BTC/ETH, 5 filings) are neutral operational tweaks effective Apr 1. Portfolio implication: favor growth infra/consumer plays amid capex cycles, monitor M&A for consolidation.

28 high priority 22 medium 50 total filings
Β· daily

S&P 500 Healthcare Sector SEC Filings β€” March 16, 2026

In the USA S&P 500 Healthcare stream, biotech and medtech firms dominate with mixed but stabilizing financials: revenues grew in devices (Smith & Nephew +6.1% YoY) while core sales declined in nutritionals (USANA -8.3% YoY), and biotechs narrowed losses (Rallybio -84% net loss YoY, HeartSciences -4% 9mo) amid pipeline catalysts. Cash positions strengthened significantly (Alto +5% to $177M funding into 2028, HeartSciences +209% to $3.4M), supported by $120M Alto raise and operational efficiencies (Rallybio opex -44% YoY). Broader filings reveal robust capital returns (SAIC $422M FY26 buybacks, Truist $10B new program, $5.2B returned 2025) and proxy season peaks with 10+ April 2026 meetings. Forward-looking optimism in healthcare via Alto's 1Q26/1H26 data/trials, Moderna's 8 oncology programs, Smith & Nephew's 6-7% CAGR RISE plan to 2028. Portfolio trends: 5/8 key HC firms improved cash/equity YoY, but margins compressed avg -150bps in 3/8 (USANA -370bps op); non-HC financials showed net income growth avg +25% YoY (SMARTFinancial +39%). Critical implications: Biotech catalysts cluster 1H26, signaling alpha in small/mid caps; monitor dilution from raises and weak bookings (SAIC Q4 btb 0.3x).

30 high priority 20 medium 50 total filings
Β· daily

Global High-Priority Regulatory Events β€” March 16, 2026

Across 50 filings in the 'Global High Priority Market Events' stream (US SEC focus, March 16, 2026), dominant themes include a surge in M&A/takeovers (9 filings: Interactive Strength-Ergatta close, Axalta-AkzoNobel merger, Urgent.ly-Agero acquisition), SPAC/de-SPAC extensions/promotions (Xanadu, FACT II, Trailblazer), and financial distress in Indian firms (MTNL defaults β‚Ή2,096 Cr overdue, Quadrant CIRP extension to May 30, 2026). Period-over-period trends show mixed revenue performance (avg -5% YoY in media/tech like Townsquare -5.2%, iQIYI -6.6%; +30-50% in select fintech/energy like Figure Tech +48.7%, WaterBridge +66%), with net losses narrowing in 6/15 reporting cos (e.g., Blend Labs -84% YoY to $7M, Urgent.ly Q4 op loss -46%) but widening in biotechs/distressed (Alto +3%, Vanguard +62-125%). Capital allocation leans defensive (Airbnb $2.5B debt refinance to 2029-2036 despite +4.4-5.25% rates; PCB dividends +11% to $0.80/share), while forward-looking catalysts cluster in H2 2026 (merger closes, proxy votes). Portfolio-level patterns flag Indian insolvency risks (3/50 negative sentiment), US M&A bullishness (positive in 70% deals), and SPAC liquidity pressures (redemptions driving trust declines). Critical implications: Opportunistic M&A in tech/defense, avoid Indian telecom distress, monitor SPAC extensions for dilution.

50 high priority 50 total filings
Β· daily

US IPO Pipeline SEC S-1 Filings β€” March 16, 2026

The IPO Pipeline stream saw limited but material activity on March 16, 2026, with two filings: MasterCraft Boat Holdings' S-4 registering shares for its February 5, 2026 merger with Marine Products, and Presidio Production Co's S-1 advancing its post-SPAC IPO in crude oil/gas production. MasterCraft's pro forma financials reveal combined net sales of $509M for YE June 30, 2025 (up from implied historical segments) but sharp income decline to $10M from historical ~$25M sum (~60% drop due to $65M goodwill, $62M intangibles amortization, and expenses), signaling earnings dilution post-merger. Presidio's filing incorporates recent March 4, 2026 credit agreement and December 31, 2025 reserve reports, with no metrics provided but neutral sentiment amid governance updates post-August 2025 SPAC merger. Cross-filing trends show pro forma balance sheet strength (MasterCraft assets $436M, equity $343M) contrasting absent financials in Presidio, highlighting marine sector consolidation versus energy de-SPAC momentum. Market implications include potential boating market share gains for MasterCraft amid cyclical recovery, while Presidio adds to oil/gas public supply; overall quiet session underscores selective IPO/M&A pipelines in niche sectors.

2 high priority 2 total filings
Β· daily

US Earnings Financial Results SEC Filings β€” March 16, 2026

Across 50 US SEC filings for Q4 2025/FY2025 earnings (filed ~March 16, 2026), mixed sentiment prevails in 80% of cases, with biotechs/pharmas (20+ firms) showing widened net losses averaging +30% YoY from R&D spikes but offset by $200M+ aggregate equity raises (e.g., Olema $205M, Zenas via licenses); banks (PCB, Orange County, Embassy) delivered +45% avg net income growth on NIM expansion to ~4% but NPAs rose 50-70% YoY signaling credit stress. Tech/software leaders like Samsara (+30% rev, 77% margins), Dell (+19% rev, $11B op cash flow), Figure (+49% rev) drove positive outliers vs sector drags (LivePerson -22% rev); energy firms mixed with NGS rentals +14% horsepower but Aemetis volumes -7-72%. Portfolio trends: Revenue +10% avg in top 20 performers, cost cuts yielded EBITDA gains in 65% (avg +50%), but cash burns persist in pre-revenue (Eve $224M loss); capital returns via bank dividends (+11% yields) and Dell $1B+ buybacks. Critical: Rising impairments/debt in 40%, but 15 firms flipped to EBITDA positive, implying turnaround alpha in cost-disciplined growth names amid macro caution.

50 high priority 50 total filings
Β· daily

US Executive Compensation Proxy SEC Filings β€” March 16, 2026

Across 43 DEF 14A filings dominated by 2026 proxy statements, overarching themes include robust 2025 financial performance in banks and energy firms (e.g., Trustmark NII +8.4% YoY to $647.2M, Marathon $4.0B net income), contrasted by cash flow deterioration (Unisys OCF -$140M from +$135.1M YoY) and SPAC distress (Trailblazer/Compass low trust balances risking dissolution). Capital returns are strong with $5.2B from Truist (+$10B buyback program), $4.5B from Marathon (dividend +10% YoY), and dividends across financials, signaling management conviction amid high say-on-pay support (Saia 96.9%). Governance enhancements like board refreshments (Truist additions, Trex retirements) and declassifications (Marathon) prevail, with reverse splits in 5 small caps/biotechs (NextPlat 1:50 max) indicating listing pressures. Period trends show revenue/earnings growth in 8/43 (avg +10-25% YoY where quantified), cost savings (Moderna 30% YoY), but expense rises (Trustmark +5.5%). A catalyst cluster of 30+ AGMs April 21-May 6, 2026, offers voting-driven volatility; favor outperformers like financials for relative strength vs. SPACs.

43 high priority 43 total filings
Β· daily

US Executive Officer Management Changes SEC β€” March 16, 2026

Across 46 SEC 8-K filings dated March 16, 2026, focused on US executive and director changes, overarching themes include orderly retirements/successions (25+ cases, e.g., KORU Medical CEO to President Kalbermatten, Helmerich & Payne CFO transition), high-materiality C-suite shakeups (9 cases, avg materiality 8/10 like Baxter CFO exit, Fortune Brands turmoil), and positive board additions (12 cases with expertise in AI/tech/power, e.g., CoStar's Nana Banerjee, Flowserve's Brian Savoy). Period-over-period trends show mixed financials where disclosed: Dragonfly Energy +15.8% YoY FY2025 revenue ($58.6M) and +34.6% gross profit but widened net loss to $(69.9M); Kaltura Q4 revenue flat YoY ($45.5M) but Adjusted EBITDA +133% to $6.3M, FY +150% to $18.6M; CEA Industries Q3 net loss $(106.6M) from 28% BNB price drop. Capital allocation highlights shareholder alignment via equity grants (Victory Capital $79.4M performance shares with 100% appreciation hurdles over 7 years; Deere $35M PSUs tied to 5-year SVA); buybacks (Boston Beer $25M 10b5-1 plan). Market implications: Transition risks in healthcare/industrials (e.g., Air Industries CEO exit no successor), alpha in expert hires for growth (Planet Fitness 20.8M members + new CFO expert), sector patterns in energy/finance stability vs. crypto volatility.

46 high priority 46 total filings
Β· daily

US Corporate Distress Financial Stress SEC Filings β€” March 16, 2026

Across 38 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is proactive debt refinancing and extension, with 18 companies (e.g., Airbnb $2.5B notes to repay 0% convertibles, Waste Connections $600M notes, Duke Energy credit extension to 2031) issuing longer-term debt at higher rates (4.4%-6.75%) to manage short-term maturities, signaling avoidance of immediate liquidity crunches amid elevated interest expenses. Real estate players like Armada Hoffler ($562M asset sale for deleveraging to 5.5x-6.5x net debt/EBITDA) and Ares Commercial (facility extension to Dec 2026) show portfolio simplification, while biotech/health firms (Alto $120M placement, Zevra debt-free post-sale) raised capital for pipelines. Period-over-period trends reveal mixed results: Urgent.ly Q4 revenue +4% YoY/gross margin +400bps to 26% but FY revenue -10% YoY/cash down to $5.3M; TeraWulf FY2025 net loss $661M on $168.5M revenue; Spirit Airlines Chapter 11 projects FY26 revenue +6.1% YoY to $3B but net loss $111M. Distress signals include Lyra Therapeutics delisting (March 17, 2026), Outlook Therapeutics going concern (cash $8.7M insufficient), Greenland Nasdaq deficiency. Forward-looking catalysts cluster mid-2026 (e.g., AHRT closings, WisdomTree acquisition Q2), with no broad insider selling but capital allocation favoring deleveraging over dividends/buybacks. Portfolio-level: Margin expansions in 3/5 reporting firms (avg +200bps QoQ) offset by revenue declines in 4/10 (avg -8% YoY), highlighting sector-specific resilience in refinancing markets.

38 high priority 38 total filings
Β· daily

US SEC Trading Suspension Halt Orders β€” March 16, 2026

Across the two filings in the USA Trading Suspensions stream, both Lyra Therapeutics (LYRA) and Greenland Technologies Holding Corp. (GTEC) face critical Nasdaq delisting risks, highlighting a pattern of small-cap compliance failures on the Nasdaq Capital Market. LYRA's withdrawal of its delisting appeal confirms trading suspension at the open on March 17, 2026, following a February 2, 2026 determination, marking an immediate negative milestone with no positive offsets. GTEC violated Listing Rule 5550(a)(2) with Class A shares closing below $1.00 for 30 consecutive business days from January 28 to March 11, 2026, but has a 180-day compliance window until September 8, 2026. No period-over-period financial trends, insider trading activity, capital allocation changes, or forward-looking guidance beyond compliance plans are disclosed, focusing attention solely on regulatory halts. Market implications include heightened illiquidity risks for LYRA shareholders and monitoring needs for GTEC's potential reverse split or cure. Portfolio-level theme: 2/2 companies exhibit deteriorating listing compliance with negative sentiment (materiality 9-10/10), signaling caution for Nasdaq small-caps amid bid price pressures.

2 high priority 2 total filings
Β· daily

US Corporate Board Director Changes SEC Filings β€” March 16, 2026

Across 46 SEC filings on USA Board Room Changes from March 16, 2026, the dominant theme is orderly executive and board transitions, with 25+ resignations/retirements (mostly neutral sentiment, no disagreements cited) balanced by 15+ appointments adding expertise in AI, finance, tech, and operations; CFO turnover is elevated at 12 instances amid retirements and family priorities. Period-over-period trends in the few financial disclosures show mixed results: Dragonfly Energy FY25 revenue +15.8% YoY to $58.6M but net loss widened to $(69.9)M; Kaltura Q4 2025 revenue flat YoY at $45.5M but Adjusted EBITDA +133% to $6.3M; CEA Industries Q3 2026 net loss $(106.6)M driven by 28% BNB price drop. Forward-looking elements include equity grants (Victory Capital $79.4M PSUs, Deere $35M PSUs), CEO successions (KORU July 1, Cerus July 1), and guidance (Dragonfly Q1 2026 rev $9.5M, Kaltura FY26 rev $181-184M). Portfolio-level patterns signal management continuity in insurance/energy/healthcare but potential disruption risks in smaller caps; positive capital allocation via buybacks (Boston Beer $25M) and incentives aligns interests, implying stable conviction despite macro headwinds.

46 high priority 46 total filings
Β· daily

US Merger & Acquisition SEC Filings β€” March 16, 2026

The March 16, 2026 snapshot reveals a vibrant US M&A and SPAC landscape with 13 filings dominated by blank check company activities (9/13) including IPOs, extensions, unit separations, and de-SPAC announcements, alongside 4 material acquisitions/completions in fitness, defense, and tech sectors. Completed deals like Interactive Strength's $8.75-14.25M Ergatta buyout and Ondas Holdings' Rotron and 4M Defense acquisitions (total ~$5M stock with 30% YoY growth earnouts) highlight strategic expansions without reported financial declines. Pending high-value de-SPACs (Abra at $750M pre-money with $10B AUM target by 2027; GNQ at $500M with Q3 2026 close) signal bullish crypto/TechBio momentum, while SPAC extensions (Bayview 4th of 6, TLGY monthly) indicate prolonged target hunts but no liquidation risks yet. No period-over-period revenue/margin declines or insider selling noted across filings; sentiments skew positive/neutral with materiality peaking at 10/10 for Metals II IPO. Portfolio trend: SPACs represent 70% activity, clustering extensions/adjournments suggesting proxy challenges but robust fundraising ($200M+ Metals II). Implications: M&A acceleration in defense/autonomous systems and digital assets offers near-term catalysts amid stable emerging growth company statuses.

13 high priority 13 total filings
Β· monthly

US Pre-Market SEC Filings Roundup β€” March 16, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with standout growth in infrastructure (WaterBridge +66% YoY revenue), fintech (Figure Technology +48.7% revenue, +574% net income), and banking (PCB Bancorp +45% net income), contrasted by declines in media (Townsquare -5.2% revenue, iQIYI -6.6%), biotech (Alto Neuroscience -3% net loss widening), and digital services (LivePerson -22% revenue). M&A activity surges with Kennedy-Wilson merger amendments requiring 2/3 vote excluding insiders, Urgent.ly acquisition by Agero, and Armada Hoffler $562M asset sale; capital returns strengthen via Amphastar $50M buyback expansion, Townsquare $0.20 dividend maintenance (11% yield), and WaterBridge $0.05 quarterly dividend initiation. Forward guidance mixed: Townsquare FY26 revenue $420-440M (-2% implied), WaterBridge EBITDA $420-460M (+7-9%); pipeline catalysts abound in biotech (Alto ALTO-101 data 1Q26). Portfolio trends show 8/15 profitable firms improving margins via cost cuts (avg op ex -20%), but 6/10 report rising debt/interest (e.g., Townsquare +32%). Real estate simplification and SPAC extensions signal defensive positioning amid volatility, with AI/quantum themes bullish (CoStar, Xanadu). Implications: Favor infra/fintech longs, monitor media turnarounds and biotech catalysts for alpha.

31 high priority 19 medium 50 total filings
Β· daily

Global High-Priority Regulatory Events β€” March 15, 2026

Across these two high-priority market event filings, themes center on operational stability amid rumors in the metals sector and upcoming earnings catalysts in IT services, both from major Indian firms with US exposure via ADRs. Hindalco's positive rumor verification highlights minimal disruption (<0.1% impact) from gas supplier force majeure, underscoring resilience in commodities amid geopolitical noise like Iran war reports. Infosys announces a high-materiality (9/10) board meeting for Q4/FY2026 results and potential dividend, signaling routine but critical capital allocation decisions under SEBI compliance. No direct period-over-period financial trends are reported in these event-driven filings, but forward-looking catalysts dominate, with Infosys' trading window closure (March 16-April 27, 2026) implying material non-public info. Portfolio-level patterns show low-risk clarification for Hindalco (materiality 3/10) versus high-impact earnings for Infosys, suggesting relative outperformance potential in IT over metals short-term. Market implications include reduced uncertainty for Hindalco and pre-earnings positioning for Infosys, with both reinforcing SEBI regulatory transparency.

2 high priority 2 total filings
Β· daily

Global High-Priority Regulatory Events β€” March 14, 2026

The 17 filings reveal a surge in high-priority distress events among Indian listed companies, dominated by insolvency proceedings (10/17), with 70% showing positive progress via settlements, unanimous approvals, and scheme sanctions, signaling potential turnarounds amid CIRP protections. Negative outliers include Reliance Communications' subsidiary fraud classification on β‚Ή375 Cr pre-CIRP loans (β‚Ή125 Cr SBI), Tijaria Polypipes' new Bank of India insolvency petition, and Olympic Cards' β‚Ή0.15 Cr loan default on β‚Ή15.5 Cr facility. No aggregate period-over-period financial trends available, but specific metrics highlight distress like Olympic's β‚Ή9.28 Cr bank borrowings and 100% creditor approvals in restructurings (e.g., Share India 99.8% equity votes). Open offers (Lykis, Satani Bearings) and minor regulatory actions (Manappuram β‚Ή2.7L penalty) add neutral-to-positive M&A/takeover themes. Three medium-risk encumbrances (Anand Rathi Wealth, India Finsec, unknown) warrant monitoring. Portfolio implications: Bullish resolution momentum for alpha in distressed assets, bearish fraud/default risks for avoidance; key catalysts cluster March-April 2026.

17 high priority 17 total filings
Β· daily

S&P 500 Consumer Staples Sector SEC Filings β€” March 13, 2026

Across 50 recent SEC filings from the USA S&P 500 Consumer Staples intelligence stream (with broader equity coverage), overarching themes include sustained capital returns via dividends and buybacks amid mixed FY2025/Q4 results, neutral-to-positive insider activity focused on planned diversification rather than opportunistic selling, and cautious forward-looking guidance with strategic reviews in non-core assets. Period-over-period trends reveal revenue growth in 7/15 detailed reporters (avg +12% YoY, e.g., monday.com +27%, CCEP +FX-neutral), but margin compression in 6/15 (avg -100bps, e.g., Velocity NIM -11bps, Aspen gross margin -2300bps), offset by efficiency gains (e.g., Fidelity D&D efficiency ratio -590bps to 60.3%). Critical developments feature CCEP's strong €20.9B revenue and €1B buyback completion signaling staples resilience, Walmart executives' 10b5-1 plans for routine sells up to $15M through 2029 (neutral conviction), and Petco/El Pollo Loco's modest sales growth (+3.6%/-2.5%) with profitability improvements. Portfolio-level patterns show 9/50 filings with dividends/buybacks (e.g., GIII $0.10, Ford 31.7M shares), indicating robust shareholder focus despite sector headwinds like flat same-store sales (El Pollo 0.1%). M&A/strategic processes (e.g., Barnwell oil/gas review, Monroe approvals) add alpha potential, while layoffs (Modular 29% workforce) flag cost pressures. Implications favor defensive staples plays with yields, monitoring catalysts like March 18 hearings and Q1 earnings.

26 high priority 24 medium 50 total filings
Β· daily

S&P 500 Industrials Sector SEC Filings β€” March 13, 2026

Across 50 SEC filings for the USA S&P 500 Industrials intelligence stream (though spanning financials, energy, healthcare), bank 10-Ks dominate with resilient growth: ~12 banks averaged 4.5% YoY asset growth, 12% YoY NII increase, and 20bps NIM expansion (e.g., Red River +25% net income, Princeton +82%), offset by rising NPAs/provisions in 4 cases (avg +200%). Industrials shine with Venture Global's landmark $20.7B CP2 LNG financing (Phase 2 FID $8.6B, no equity needed, targeting 100+ MTPA capacity), Ducommun's record $824.7M revenue (+49% stock gain under VISION 2027), and ArcBest's $4B revenue/$86M returns despite freight weakness. Capital allocation trends positive: 5 dividends (GIII $0.10, Designer $0.05), buybacks (First Northern 1M shares thru Apr'26), stock div (First Northern 5% payable 3/25). Forward-looking catalysts include Better Home's Q1'26 loan vol guide $1.4-1.55B (post +56% YoY Q4), Tonix cash runway to Q1'27, and proxy meetings clustered Apr-May'26. Mixed sentiment (60% mixed/neutral) signals stability but credit watch; overweight NII-expanders like Fidelity D&D (+16.7% NII), avoid NPA outliers like Isabella (+553%). Portfolio implication: Industrials/financial hybrids offer defensive alpha via returns/M&A amid macro caution.

34 high priority 16 medium 50 total filings
Β· daily

S&P 500 Energy Sector SEC Filings β€” March 13, 2026

Across these 7 diverse SEC filings (primarily real estate, banking, pharma/consumer health despite energy stream context), overarching themes include mixed financial performance with modest revenue growth offset by widening losses, impairments, and operational pressures in real estate entities. Period-over-period trends reveal revenue increases (BRT +1.5% YoY to $97M, Copper lease income +2% YoY to $96M, John Marshall NII +18.6% YoY) but declining profitability (BRT FY net loss to $(11.9M) from $(9.8M), Copper net income -36% YoY to $47M, same-store NOI flat/declining across BRT/Copper). Real estate-focused filings (BRT x2, Copper, Kaanapali) dominate with portfolio expansions/sales, higher debt costs, and impairments, while banking (John Marshall) shows robust +24% YoY net income growth to $21.2M and Haleon delivers clean audits. Capital allocation leans toward share repurchases (BRT 321k shares) and dividends (maintained $0.25 Q at BRT, $0.30 at John Marshall), but no insider trading patterns noted. Critical developments like Bioxytran's impairments/leadership changes signal distress, while land sales (Kaanapali +$10.3M gain) and bank asset growth (+4.4% to $2.33B) offer pockets of strength. Market implications: Heightened caution on real estate amid NOI declines and debt maturities, selective opportunities in growing financials; portfolio-level trend of margin compression (e.g., Copper NOI -7%, BRT AFFO flat) suggests broader sector vulnerability.

6 high priority 1 medium 7 total filings